mRNA-lipid nanoparticles: Quality control releasing testing and characterization

The regulatory authorizations and approvals of the Pfizer and Moderna COVID-19 vaccines proved to be a trailblazer for the mRNA-LNP modality and opened the pathway for regulatory approvals of a whole raft of similar mRNA-based products.